Search results
Results from the WOW.Com Content Network
Chronic lymphocytic leukemia (CLL) is a type of cancer that affects the blood and bone marrow. [8] [9] In CLL, the bone marrow makes too many lymphocytes, which are a type of white blood cell.
Treatment may involve some combination of chemotherapy, radiation therapy, targeted therapy, and bone marrow transplant, with supportive and palliative care provided as needed. [3] [6] Certain types of leukemia may be managed with watchful waiting. [3] The success of treatment depends on the type of leukemia and the age of the person.
The role of Bcl3 in solid tumors was established through the ability of Bcl3 to promote metastasis without affecting primary tumor growth or normal mammary function, within models of ErbB2-positive breast cancer. [18] Further research has uncovered the role of Bcl3 in promoting progression of other solid tumors.
The most common secondary neoplasm is secondary acute myeloid leukemia, which develops primarily after treatment with alkylating agents or topoisomerase inhibitors. [109] Survivors of childhood cancer are more than 13 times as likely to get a secondary neoplasm during the 30 years after treatment than the general population. [ 110 ]
Chlorambucil, sold under the brand name Leukeran among others, is a chemotherapy medication used to treat chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, and non-Hodgkin lymphoma. [2] For CLL it is a preferred treatment. [3] It is given by mouth. [3] Common side effects include bone marrow suppression. [3]
B-cell prolymphocytic leukemia, referred to as B-PLL, is a rare blood cancer. It is a more aggressive, but still treatable, form of leukemia . Specifically, B-PLL is a prolymphocytic leukemia (PLL) that affects prolymphocytes – immature forms of B-lymphocytes and T-lymphocytes – in the peripheral blood, bone marrow, and spleen.
Precursor B-cell lymphoblastic leukemia is a form of lymphoid leukemia in which too many B-cell lymphoblasts (immature white blood cells) are found in the blood and bone marrow. It is the most common type of acute lymphoblastic leukemia (ALL). It is sometimes additionally classified as a lymphoma, as designated leukemia/lymphoma. ALL is the ...
Additional treatments such as Chimeric antigen receptor T cell immunotherapy are being used and further studied. [2] Acute lymphoblastic leukemia affected about 876,000 people globally in 2015 and resulted in about 111,000 deaths. [14] [10] It occurs most commonly in children, particularly those between the ages of two and five.